Last reviewed · How we verify
long acting injectable risperidone, High Dose Group — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
long acting injectable risperidone, High Dose Group (long acting injectable risperidone, High Dose Group) — Northwestern University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| long acting injectable risperidone, High Dose Group TARGET | long acting injectable risperidone, High Dose Group | Northwestern University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- long acting injectable risperidone, High Dose Group CI watch — RSS
- long acting injectable risperidone, High Dose Group CI watch — Atom
- long acting injectable risperidone, High Dose Group CI watch — JSON
- long acting injectable risperidone, High Dose Group alone — RSS
Cite this brief
Drug Landscape (2026). long acting injectable risperidone, High Dose Group — Competitive Intelligence Brief. https://druglandscape.com/ci/long-acting-injectable-risperidone-high-dose-group. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing